We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to ...

Truist raised the firm’s price target on Elevance Health (ELV) to $510 from $480 and keeps a Buy rating on the shares as part of a broader ...

Guggenheim just gave Elevance Health a shiny new Buy rating and a bold $518 price target, despite the current $430.90 tag.

Fintel reports that on April 9, 2025, Guggenheim initiated coverage of Elevance Health (NYSE:ELV) with a Buy recommendation.

Shares of Elevance Health Inc. ELV rallied 1.11% to $435.68 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 9.52% to ...

Indianapolis-based health Elevance Health’s board is recommending its investors reject a shareholder proposal that asks the ...